相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
K Wyatt et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis
Saskia M. Rombach et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2014)
A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance
L. van der Tol et al.
JOURNAL OF MEDICAL GENETICS (2014)
Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease
Martin Wagner et al.
BMC NEPHROLOGY (2014)
Home-based infusion therapy - a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease
M. Beck et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2013)
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
F. Weidemann et al.
JOURNAL OF INTERNAL MEDICINE (2013)
A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease
D. A. Hughes et al.
MOLECULAR GENETICS AND METABOLISM (2013)
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Saskia M. Rombach et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Saskia M. Rombach et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Measuring the Quality of Life in Patients with Multiple Sclerosis in Clinical Practice: A Necessary Challenge
Karine Baumstarck et al.
MULTIPLE SCLEROSIS INTERNATIONAL (2013)
P03—Excessive Daytime Sleepiness is a Common Symptom in Fabry Disease
T. Duning et al.
CLINICAL THERAPEUTICS (2012)
P08—Quality of Life did not Worsen for 7 Years in Enzyme-Replacement Therapy Recipients with Fabry Disease
I. Kantola et al.
CLINICAL THERAPEUTICS (2012)
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Kazuya Tsuboi et al.
GENETICS IN MEDICINE (2012)
Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
Uma Ramaswami et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
Prevalence of symptoms in female Fabry disease patients: a case-control survey
Machtelt G. Bouwman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2012)
Upregulation of inward rectifying currents and Fabry disease neuropathy
Nimeshan Geevasinga et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2012)
Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria
Thomas P. Mechtler et al.
LANCET (2012)
Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases
Chiara Cazzorla et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Wills Hughes-Wilson et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
Neuropsychiatric symptoms and brain structural alterations in Fabry disease
I. Schermuly et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS)
M. -A. Barba-Romero et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life
Machtelt G. Bouwman et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS-the Fabry Outcome Survey
Derralynn A. Hughes et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
Bouwien E. Smid et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Carla E. M. Hollak et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
Torquil Watt et al.
GENETICS IN MEDICINE (2010)
Ocular manifestations of Fabry disease within in a single kindred
Albert M. Morier et al.
OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION (2010)
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
A. Mehta et al.
LANCET (2009)
Functional and structural nerve fiber findings in heterozygote patients with Fabry disease
Anette Torvin Moller et al.
PAIN (2009)
Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters
J. W. Koskenvuo et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Central nervous system involvement in Anderson Fabry disease: a clinical and MRI retrospective study
S. Buechner et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin et al.
JOURNAL OF PAIN (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry
Robert J. Hopkin et al.
PEDIATRIC RESEARCH (2008)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Gastrointestinal symptoms in 342 patients with Fabry disease: Prevalence and response to enzyme replacement therapy
Bjoern Hoffmann et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Neurology of Fabry disease
M. Low et al.
INTERNAL MEDICINE JOURNAL (2007)
Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
The Dutch Fabry cohort:: Diversity of clinical manifestations and Gb3 levels
A. C. Vedder et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
U. Ramaswami et al.
ACTA PAEDIATRICA (2007)
Endocrine dysfunction in patients with Fabry disease
A. Faggiano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
High incidence of later-onset Fabry disease revealed by newborn screening
Marco Spada et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease
Natalie Jansen Street et al.
GENETICS IN MEDICINE (2006)
Natural history of Fabry disease in females in the Fabry outcome survey
PB Deegan et al.
JOURNAL OF MEDICAL GENETICS (2006)
The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease a cross-sectional study of a large cohort of clinically affected heterozygous women
S Gupta et al.
MEDICINE (2005)
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D
SJ Walters et al.
QUALITY OF LIFE RESEARCH (2005)
Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study
Y Eto et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease
KW Wyrwich et al.
HEALTH SERVICES RESEARCH (2005)
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)
B Hoffmann et al.
JOURNAL OF MEDICAL GENETICS (2005)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
WR Wilcox et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Fabry disease: Renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications
SM Meehan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study
F Baehner et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Quality of life of patients with Fabry disease
KF Gold et al.
QUALITY OF LIFE RESEARCH (2002)
Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention
AH Miners et al.
QUALITY OF LIFE RESEARCH (2002)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males
KD MacDermot et al.
JOURNAL OF MEDICAL GENETICS (2001)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females
KD MacDermot et al.
JOURNAL OF MEDICAL GENETICS (2001)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
CM Eng et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
分享论文
